Biotechnology company developing medication and synthesis processes for the medical psychedelic market Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSFT) together with medical research and drug development company Intervivo Solutions Inc. have given updates on a psychedelic evaluation program they are conducting.
The companies announced availability of their first data set as part of the Cooperative Psychedelics Evaluation Platform (COPE) program.
This program was unveiled in March with an aim creating world’s first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs.
Some of psychedelic drugs being studied in the program include LSD, 5-MeO-DMT, DMT, psilocybin among others. The companies released preliminary data on the COPE program which focuses on psilocybin and further demonstrating that the clinical exposure levels recorded in humans correlates well to exposure and efficacy measures observed in mice.
This report strengthens the predictive value of InterVivo’s selected behavioral assays and animal models. Making an assumption that these relationship is replicated in psychedelics compounds, this data should be able to support translation of human clinical study to InterVivo’s behavioral model platform.
“Despite the widespread interest in the therapeutic potential of psychedelics, there is relatively little preclinical data relating their efficacy/safety profiles and how these relate to plasma and CNS exposures, and PK property. Developing this knowledge base for psychedelics such as LSD and psilocybin, currently being evaluated in the clinic, will undoubtedly help the value assessment of newer psychedelics in development,” said the CSO of Intervivo, Dr. Guy Higgins.